FDA calendar · December 2023 · built from SEC filings

PDUFA dates December 2023: FDA calendar and catalysts.

Updated Snapshot 20261116T112050ZBuilt

0 PDUFA dates fell in December 2023. The FDA calendar also recorded 43 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in December 2023

No PDUFA dates are disclosed for this period as of November 16, 2026.

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

December 2023: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
December 1, 2023Saphnelo (anifrolumab-fnia)AZNLabel expansion—ApprovedopenFDA Drugs@FDA
Dec 2023Month disclosedJAKAFI (ruxolitinib)INCYComplete Response Letter—CRL issuedSEC Form 10-Q
December 1, 2023Jaypirca (pirtobrutinib)LLYLabel expansion—ApprovedopenFDA Drugs@FDA
Dec 2023Month discloseddesignMDCXFDA approval—ApprovedSEC 8-K Exhibit 99.1
Dec 2023Month disclosedMVASI® (bevacizumab)OTLKNDA/BLA submission—Completedsec_424b
Dec 2023Month disclosedTLX250TLXNDA/BLA submission—CompletedSEC 8-K Exhibit 99.1
Dec 2023Month disclosedNEREUSTM (tradipitant)VNDAFDA approvalvomiting inducedApprovedSEC Form 10-K
Dec 2023Month disclosedNEREUSTM (tradipitant)VNDANDA/BLA accepted—CompletedSEC Form 10-K
December 5, 2023FABHALTA® (iptacopan)NVSFDA approvalTo treat paroxysmal nocturnal hemoglobinuriaApprovedFDA Novel Drug Approvals
December 7, 2023ZUNVEYL (benzgalantamine)ACOGNDA/BLA accepted—Completedsec_s1
December 12, 2023expansionADMAFDA approval—ApprovedSEC Form 10-Q
December 12, 2023CINVANTI®HRTXNDA/BLA submission—CompletedSEC Form 10-Q
December 12, 2023vascularHUMANDA/BLA submission—CompletedSEC Form 10-Q
December 13, 2023Idose Tr (travoprost)GKOSFDA approval—ApprovedopenFDA Drugs@FDA
December 14, 2023WELIREG® (belzutifan)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
December 14, 2023Cibinqo (abrocitinib)PFELabel expansion—ApprovedopenFDA Drugs@FDA
December 15, 2023ZORYVE (roflumilast)ARQTFDA approvalseborrheic dermatitis in individuals aged 9 years and older, with no limitationApprovedSEC Form 10-Q
December 15, 2023KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
December 19, 2023Erleada (apalutamide)JNJLabel expansion—ApprovedopenFDA Drugs@FDA
December 21, 2023WAINUA (eplontersen)AZNFDA approvalTo treat polyneuropathy of hereditary transthyretin-mediated amyloidosisApprovedFDA Novel Drug Approvals
December 21, 2023BRUKINSA® (zanubrutinib)ONCLabel expansion—ApprovedopenFDA Drugs@FDA
December 22, 2023Udenyca (pegfilgrastim-cbqv)CHRSLabel expansion—ApprovedopenFDA Drugs@FDA
December 31, 2023—TARSFDA approval—ApprovedSEC Form 10-K
December 31, 2023XOLREMDI® (mavorixafor)XFORNDA/BLA acceptedpeople aged 12 years and older with WHIM syndromeCompletedSEC Form 10-K

December 2023: dated readouts

DateDrugCompanyEventIndicationStatusSource
Dec 2023Month disclosed—ASNDTopline readout—PositiveSEC Form 8-K
Dec 2023Month disclosedMYQORZO® (aficamten)CYTKTopline readout—PositiveSEC Form 10-Q
Dec 2023Month disclosedMP0533MOLNInterim readout—PositiveSEC Form 10-K
Dec 2023Month disclosedNST003NRSNTopline readoutALS, reportingMet primary endpointsec_s1
Dec 2023Month discloseddeucrictibant (PHA121)PHVSTopline readout—Positivesec_424b
Dec 2023Month disclosed—TARSTopline readoutMGD in patients with Demodex mitesPositiveSEC Form 10-Q
December 8, 2023—CLRBTopline readout—PositiveSEC Form 10-K

December 2023: trial starts and primary completions

DateDrugCompanyEventIndicationStatusSource
Dec 2023Month disclosedOvapreneDARETrial start—CompletedSEC 8-K Exhibit 99.1
Dec 2023Month disclosedAMX0035AMLXTrial start—CompletedSEC Form 10-Q
Dec 2023Month disclosedCC-42344COCPTrial start—CompletedSEC 8-K Exhibit 99.1
Dec 2023Month disclosedArazlo® (tazarotene)GRITrial start—CompletedSEC Form 10-K
Dec 2023Month discloseddeucrictibant (PHA121)PHVSTrial start—CompletedSEC 8-K Exhibit 99.1
December 19, 2023foralumab (TZLS-401)TLSATrial startnon-active SPMSCompletedsec_424b
Dec 2023Month disclosedAGEN1777AGENTrial start—CompletedSEC Form 10-Q
Dec 2023Month disclosedATR-12AZTRTrial start—Completedsec_s1
Dec 2023Month disclosedCLN-617CGEMTrial startadvanced solid tumorsCompletedSEC Form 10-K
Dec 2023Month disclosedCLN-049CGEMTrial startAML and measurable residual diseaseCompletedSEC Form 10-K
Dec 2023Month disclosedPAS-004KTTATrial startMAPK pathway-driven advanced tumorsCompletedSEC Form 10-Q
Dec 2023Month disclosedSENTI-202SNTITrial starthematologic malignanciesCompletedSEC Form 10-Q

Questions

What PDUFA dates are in December 2023?

0 PDUFA dates fell in December 2023. The FDA calendar also recorded 43 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.